HOMEPPL
29.9.2021 00:03:09 CEST | Business Wire | Press release
Spotahome , the Spanish-based residential platform which manages 200,000 properties in 29 different countries across Europe, has signed an agreement with UK-based tenant due diligence and guarantee firm Homeppl to provide its landlords with a tenant referencing and guarantor service for its medium and long-term lets.
With the world opening-up and embracing a post-pandemic life, demand for both medium and long-term rentals has tripled, so being able to approve tenants quickly is imperative. But the risk of tenant fraud remains high, so it is vital that landlords have secure tenant referencing systems in place.
Homeppl’s solution combines fraud detection tests, behavioural analysis and financial algorithms, as well as Open Banking data, to assess the true transactional ability of consumers from all over Europe. It has a 0% default rate, and Homeppl is so confident in its referencing solution that it also offers guarantid - a service where it acts as a guarantor for tenants it approves - giving landlords more protection and tenants more freedom.
Spotahome has embedded the Homeppl tenant and guarantor services in a new premium package for its landlords; 2,000 have already signed up in Spotahome Premium service, with numbers expected to reach 10,000 by the end of the year.
Through this partnership with Homeppl, Spotahome - already a pioneer in digital rental due to its innovative virtual tours - is further transforming the rental process in Europe making it easier for tenants to rent and safer for landlords. Thanks to Homeppl’s service, Spotahome is reducing entry barriers to rent for tenants by no longer having to charge an initial payment of between one and three months’ rent, while also providing financial and legal security to landlords by mitigating fraud, guaranteeing rent and covering the cost of any damage to property.
CEO and Co-founder of Spotahome, Alejandro Artacho said: “ This new service offered to “Premium Spotahome Landlords” in partnership with Homeppl, makes Spotahome the only platform offering rentals with no deposit and Landlords guaranteed across multiple countries in Europe and it is just a step towards making rentals more accessible, and at the same time more secure for both tenants and landlords. In the following months, Spotahome will continue to launch new functionalities becoming the European digital rental platform of reference.
CEO of Homeppl Alexander Siedes said: “With a post-COVID recovery underway, we’re delighted that Spotahome – one of the biggest online rental firms in the world – has chosen us as their tenant referencing and tenant guarantor provider. This partnership will help support rental mobility across Europe, enabling tenants to explore new cities and rent with greater freedom while protecting landlords from any financial or legal risk.”
ENDS
About Homeppl:
Homeppl creates financial inclusion. The tech for good business brings equality of opportunity to consumers of financial and property products. This allows businesses to safely transact with more consumers, including those who have been living outside the UK, are self-employed or students, and other people without a credit file. To do this, they specialise in rental data validation, and risk assessment. So far they’ve validated 100,000+ people from 80+ countries with 0 default. As a result, Homeppl are confident in finding the best tenants.
Homeppl's overall aim is to let landlords and agencies assess any tenant, and guarantee rent.
For more information: www.homeppl.com
About Spotahome:
Spotahome is one of the European leading platforms created in 2014 specialized in mid-to-long term furnished accommodation.
For more information: www.spotahome.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928006038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom